Tag: CAR T-cell

FDA Grants Regenerative Medicine Advanced Therapy, Fast Track Designations to Novel CAR T-Cell Therapy for Relapsed, Refractory B-cell Non-Hodgkin Lymphoma

C-CAR039 showed positive efficacy and safety data in patients with relapsed or refractory B-cell non-Hodgkin lymphoma. Officials with the FDA have granted both Regenerative Medicine Advanced Therapy (RMAT) Designation and Fast Track Designation to C-CAR039, a novel autologous bi-specific chimeric antigen receptor (CAR) T-cell therapy, for the treatment of patients…

Continue Reading FDA Grants Regenerative Medicine Advanced Therapy, Fast Track Designations to Novel CAR T-Cell Therapy for Relapsed, Refractory B-cell Non-Hodgkin Lymphoma

Brem Looks at Multiple Treatments for Patients With DLBCL

During a Targeted OncologyTM Case-Based Roundtable event, Elizabeth A. Brem, MD, an assistant professor in Division of Hematology/Oncology, Department of Medicine at UC Irvine Health in Los Angeles, CA, moderated a discussion about a 43-year-old woman with diffuse large B-cell lymphoma. Targeted Oncology™: What therapeutic options would you consider at…

Continue Reading Brem Looks at Multiple Treatments for Patients With DLBCL

Barriers to Loncastuximab Before CAR T-Cell Therapy in DLBCL

DISCUSSION QUESTIONS Do you foresee any barriers to using loncastuximab tesirine (Zynlonta) in diffuse large B-cell lymphoma (DLBCL)?​ If loncastuximab were covered by insurance, would you use it in the second line for patients who decline transplant?​ DEVA NATHAN, MD: I have different question. Are you willing to replace R-CHOP [rituximab…

Continue Reading Barriers to Loncastuximab Before CAR T-Cell Therapy in DLBCL

The Future of Targeted Therapies in DLBCL

In an interview with Targeted Oncology, Thomas Habermann, MD discusses the current unmet needs in the DLBCL space, along with the future of targeted therapies. While rituximab (Rituxan), cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) is a highly effective therapy for diffuse large B-cell lymphoma (DLBCL). However, major unmet clinical needs still exist for patients with…

Continue Reading The Future of Targeted Therapies in DLBCL

Fate Therapeutics Highlights Positive Durability of

6 of 10 Patients Naïve to Treatment with Autologous CAR T-cell Therapy Continue in Ongoing Response at Median Follow-up of 9.1 Months, including 4 Patients with >6 Months Follow-up, at ≥90 Million FT516 Cells per Dose 3 of 8 Patients Previously Treated with Autologous CAR T-cell Therapy Achieve Complete Response…

Continue Reading Fate Therapeutics Highlights Positive Durability of

Real-World Study of Tisagenlecleucel in R/R B-Cell Non-Hodgkin Lymphomas Shows Efficacy, Safety

Real-world data on tisagenlecleucel in patients with relapsed/refractory B-cell lymphoma was consistent with the phase 2 JULIET trial, demonstrating favorable efficacy and safety. Real-world data on the use of tisagenlecleucel (Kymriah) showed greater efficacy and a favorable safety profile, according to updated findings from a study of the Center for…

Continue Reading Real-World Study of Tisagenlecleucel in R/R B-Cell Non-Hodgkin Lymphomas Shows Efficacy, Safety

Tafasitamab and Lenalidomide Combo Yields Higher OS vs Standard Options in Relapsed/Refractory DLBCL

Treatment with tafasitamab (Monjuvi) and lenalidomide (Revlimid) provided an overall survival (OS) benefit vs standard options in a population of patients with autologous stem cell transplant (ASCT)–ineligible relapsed/refractory diffuse large B-cell lymphoma (DLBCL), according to findings from an expanded analysis of RE-MIND2 study (NCT04697160) that was presented at the 2021…

Continue Reading Tafasitamab and Lenalidomide Combo Yields Higher OS vs Standard Options in Relapsed/Refractory DLBCL

EFS improvement with axi-cel CAR-T a ‘breakthrough’ in second-line treatment of DLBCL

December 11, 2021 3 min read Source/Disclosures Published by: Source: Locke FL, et al. Abstract 2. Presented at: ASH Annual Meeting and Exposition; Dec. 11-14, 2021. Disclosures: Kite Pharma sponsored this study. Leslie reports advisory board, consultant or speakers bureau roles with AbbVie, AstraZeneca, BeiGene, Celgene/Bristol Myers…

Continue Reading EFS improvement with axi-cel CAR-T a ‘breakthrough’ in second-line treatment of DLBCL

Tafasitamab/Lenalidomide Improves OS Over Other Options in Retrospective Relapsed/Refractory DLBCL

The combination of tafasitamab (Monjuvi) and lenalidomide (Revlimid) prolonged median overall survival (OS) compared with other standard options for autologous stem cell transplant (ASCT)-ineligible patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL), according to a closely matched expanded analysis of the observational, retrospective RE-MIND2 (NCT04697160) study presented at the…

Continue Reading Tafasitamab/Lenalidomide Improves OS Over Other Options in Retrospective Relapsed/Refractory DLBCL

Choosing a Third-Line Treatment for Refractory DLBCL

DISCUSSION QUESTION What are the key factors that influence your decision making for third-line therapy? PAOLO CAIMI, MD: What are the key factors that influence your decision in choice of regimen for patients who are in the third-line therapy? Any comments about the things that you use when you’re thinking about…

Continue Reading Choosing a Third-Line Treatment for Refractory DLBCL